SpectronRx is a radiopharmaceutical CDMO/CMO that is FDA and EMA-inspected. We are licensed to handle multiple pharmaceutical-grade Therapeutic and Diagnostic isotopes, including Pb-212, Lu-177, Ac-225, and I-131, for various clinical applications. We operate under a quality program that has been inspected by the FDA with approved drugs FDG, NaF and Ammonia. SpectronRx also provides labeling and contract manufacturing services related to Lu-177, Ac-225, I-131, I-124, In-111, Zr-89, Cu-64 and F-18.
| Website | http://www.spectronrx.com |
| Revenue | $7.5 million |
| Employees | 143 (111 on RocketReach) |
| Founded | 2004 |
| Phone | +1 317-459-8315 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+7 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing |
| Keywords | Radioactive Isotopes, Radiopharmaceutical Development, Cdmo Services, Nuclear Medicine, Pharmaceutical Manufacturing, Clinical Applications, Contract Manufacturing, Pharmaceutical Contract Manufacturing, Drug Manufacturing |
| Competitors | Siemens, Roche, Thermo Fisher Scientific, Abbott, BD, Quest Diagnostics, Merck Group, Labcorp, Eurofins, Fisher Scientific +38 more (view full list) |
Looking for a particular SpectronRx employee's phone or email?
The SpectronRx annual revenue was $7.5 million in 2026.
John Zehner is the CEO of SpectronRx.
111 people are employed at SpectronRx.